A potential new Alzheimer's drug represses the harmful inflammatory response of the brain's immune cells, reducing disease pathology, preserving neurons and improving cognition in preclinical tests.

There has been progress in developing treatments for Alzheimer’s disease that reduce amyloid-beta protein. However, there is a need for treatments that also reduce inflammation as it has been hard to ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, a pioneer in machine learning for drug discovery and development, today announced a new collaboration with Eli Lilly and Company (Lilly) to ...

Juan Casado Cordón, Professor of Physical Chemistry at the University of Malaga, considers graphene—an infinite layer of carbon atoms—as one of the greatest discoveries of the last 20 years due to its ...

Genesis’ proprietary foundation model – Pearl – outperforms frontier models, including AlphaFold 3, on key benchmarks that predict utility in real-world drug discovery Pearl’s performance improved ...

A molecular model shows two macrocycles interlocked like links in a chain, with additional atoms attached on the side of one ring. This conceptual version of the catenane made by Michael Kathan and ...

Though drug developers have achieved some progress in treating Alzheimer’s disease with medicines that reduce amyloid-beta protein, other problems of the disease including inflammation, continue ...